Document Detail

Test-Retest, Responsiveness, and Minimal Important Change of the Ability to Perform Physical Activities of Daily Living Questionnaire in Individuals with Type 2 Diabetes and Obesity.
MedLine Citation:
PMID:  23016515     Owner:  NLM     Status:  Publisher    
Abstract Background: The Ability to Perform Physical Activities of Daily Living Questionnaire (APPADL) measures the self-reported ability of individuals with type 2 diabetes mellitus (T2DM) and obesity to perform daily physical activities. The primary objective of this study was to estimate APPADL test-retest reliability, responsiveness, and minimal important change (MIC). Subjects and Methods: Study participants were individuals with T2DM and body mass index ≥30 kg/m(2) enrolled in clinical weight loss programs in the United States. Data were obtained for clinical measures, APPADL, and other patient-reported instruments. APPADL test-retest reliability was estimated with intraclass correlation coefficient. To estimate responsiveness in a subgroup of participants, baseline and 6-month data were analyzed using paired t test and calculation of responsiveness indices (e.g., effect size [ES]). To estimate MIC, both distribution-based and anchor-based methods were used. Results: Test-retest data for 106 study participants (mean age, 52 years; 69% female; 31% white; mean body mass index, 38 kg/m(2)) yielded an intraclass correlation coefficient of 0.91. In the subgroup (n=40) used to estimate responsiveness, weight was significantly less at end point than at baseline (mean, 222.0 vs. 231.9 pounds; P<0.001, ES=0.24), and APPADL scores were significantly better than at baseline (mean, 77.0 vs. 70.8; P=0.01, ES=0.32). Results of distribution- and anchor-based methods to establish MIC suggest values of 6-14 points (0-100 scale). Conclusions: The APPADL has demonstrated reliability and validity. In addition, it has demonstrated responsiveness to weight loss in individuals with T2DM and obesity, thereby making it a potentially valuable tool in the evaluation of weight loss interventions (e.g., antihyperglycemic medications that produce weight loss) targeted toward patients with T2DM.
Risa P Hayes; Elisabeth M Schultz; April N Naegeli; Bradley H Curtis
Related Documents :
11419705 - Investigations on the carbohydrate moieties of glycoprotein allergens.
18676025 - Allergen-specific ige in icelandic horses with insect bite hypersensitivity and healthy...
9753365 - The influence of house characteristics on the effectiveness of radon remedial measures.
10678725 - Allergy to an occupational allergen (sapelli wood) in a child.
17520065 - Meeting report: alternatives for developmental neurotoxicity testing.
21748525 - Differences in prevalence of tuberculosis in indigenous and crossbred cattle under exte...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-9-27
Journal Detail:
Title:  Diabetes technology & therapeutics     Volume:  -     ISSN:  1557-8593     ISO Abbreviation:  Diabetes Technol. Ther.     Publication Date:  2012 Sep 
Date Detail:
Created Date:  2012-9-28     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  100889084     Medline TA:  Diabetes Technol Ther     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
1 Global Health Outcomes, Eli Lilly and Company , Indianapolis, Indiana.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Evidence for pathogenicity of autoreactive T cells in autoimmune bullous diseases shown by animal di...
Next Document:  Sensor-Augmented Pump Therapy at 36 Months.